Clinical Trials Logo

BRIP1 Gene Mutation clinical trials

View clinical trials related to BRIP1 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT06392841 Not yet recruiting - BRCA2 Gene Mutation Clinical Trials

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

HARMONY
Start date: December 2024
Phase: Phase 2
Study type: Interventional

This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.

NCT ID: NCT05420064 Recruiting - BRCA1 Mutation Clinical Trials

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate a cascade genetic testing intervention. Cascade testing is the process of offering genetic testing to people who are at risk of having inherited a possibly harmful gene change that has been found in their family. This process is repeated as more people within the family are found to have the gene change. The study will look at how often genetic testing occurs when healthcare providers have permission to reach out to family members to recommend genetic testing and to help those who are interested get tested. The study will look at whether this cascade testing intervention is practical and effective. The study would like to see how this approach of healthcare providers reaching out directly to family members compares with the usual approach of patients telling their family members about the recommendation to get genetic testing.

NCT ID: NCT04294927 Recruiting - Ovarian Cancer Clinical Trials

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

TUBA-WISP-II
Start date: March 1, 2020
Phase: N/A
Study type: Interventional

The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

NCT ID: NCT04030559 Recruiting - Prostate Carcinoma Clinical Trials

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Start date: February 25, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT04009148 Recruiting - BRIP1 Gene Mutation Clinical Trials

Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

Start date: March 1, 2019
Phase:
Study type: Observational

Identification of BRCA mutations in ovarian cancer patients may help guide cancer therapies, prognosis, post-operative screening, and other preventative treatments beyond the initial diagnosis. Likewise, genetic testing of ovarian cancer patients for these germline mutations provides invaluable information for families regarding cancer risk, genetic testing, and subsequently indication for risk-reducing surgery. Cascade testing provides a unique opportunity to identify carriers of a deleterious BRCA mutation which can allow for surgical and chemoprevention of prevention of ovarian cancer. There is currently no literature on the rates of referral for the family members.

NCT ID: NCT03377556 Completed - BRCA1 Gene Mutation Clinical Trials

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Start date: March 3, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talazoparib works in treating patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer that has come back after previous treatment. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03344965 Active, not recruiting - Clinical trials for Metastatic Breast Cancer

Olaparib In Metastatic Breast Cancer

Start date: April 1, 2018
Phase: Phase 2
Study type: Interventional

This research study is for patients with metastatic breast cancer. - Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA) when it becomes damaged. - This aspect of the cancer may cause it to be more sensitive - that is, more effectively killed by certain types of drugs such as the study agent being evaluated in this trial, Olaparib. - Olaparib is a type of drug known as a PARP inhibitor. Some types of breast cancer and ovarian cancer share some basic features that make them sensitive to similar treatments. Information from those other research studies suggests that this drug may help to treat metastatic breast cancer. - This study will evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in one of the other genes that function with BRCA1 and BRCA2 to repair damaged DNA .This mutation may have been inherited from a parent, or may have developed only in the tumor. - This study will also evaluate whether olaparib is effective in breast cancer patients whose tumor has a mutation in BRCA1 or BRCA2 that was acquired by the tumor, but not inherited.

NCT ID: NCT02993068 Recruiting - HER2/Neu Negative Clinical Trials

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Start date: April 18, 2017
Phase: N/A
Study type: Interventional

This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their risk of cancer.